Viral Vector Production

Animal-Origin-Free Excipients and Cell Culture Components for Viral Vector Production

Gene therapy has moved from promise to scale. The FDA has approved multiple AAV-based therapies, lentiviral-vector-based CAR-T therapies, and oncolytic viral therapies, with hundreds more in the clinical pipeline. As the field matures, the bottleneck has shifted from clinical validation to manufacturing: producing enough functional viral vector, consistently and at acceptable cost per dose, to meet commercial demand.

Viral vector manufacturing is unforgiving. Vectors like AAV and lentivirus are propagated in host cells such as HEK293 and then carried through a downstream process that exposes the particle to repeated shear, surface, thermal, and freeze-thaw stress. Cumulative titer losses across the downstream train can exceed 90%. Every percentage point of recovery translates directly to cost per dose, batch consistency, and ultimately, patient access.

InVitria’s animal-origin-free recombinant proteins address two pressure points in this workflow: cell culture media performance during upstream production, and viral particle stabilization during downstream processing and formulation. All InVitria products are defined, recombinant, and free of animal-origin components, eliminating donor variability and adventitious agent risk that regulators scrutinize in viral vector filings.

Stabilization for Downstream Processing and Formulation

• Optibumin 25 — liquid recombinant human albumin (25% w/v) for stabilizing viral vector particles across TFF, freeze-thaw, process hold, and sterile filtration. Recent internal data show up to 2× cumulative recovery of infectious lentiviral vector across downstream processing.
• Exbumin — lyophilized excipient-grade recombinant human albumin for improving stability of viral vector particles in injectable therapeutics.

Upstream Cell Culture

• Optiferrin — recombinant human transferrin for managing iron in serum-free or serum-reduced HEK293 and other host cell culture applications.
• ITSE Animal Free and related insulin-transferrin supplements — provide rh-insulin, rh-transferrin, and selenium, with or without ethanolamine and rh-albumin, for serum-free or serum-reduced culture.

Regulatory Precedent

InVitria recombinant albumin is used as a stabilizer in ERVEBO, the FDA, EMA, and PMDA-approved VSV-pseudotyped enveloped viral vaccine. That precedent supports the regulatory path for related enveloped viral vector products, including lentivirus.

Related Resources